Vericel reported 1Q22 orthopedic sales of $26 million, +9.2% vs. 1Q21.
According to the company, MACI vastly outperformed the overall cartilage repair market. Additionally, the Vericel active surgeon population grew in the double digits during the first quarter while March brought the second-highest biopsy volume since launch.
The company previously estimated a $10 million backlog coming into 2022 and said the first quarter did little to process it. Still, despite the better than expected start to the year, Vericel opted to maintain its MACI guidance of $132 million to $141 million. That range represents growth been +18% and +26%.
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. Orthopedic sales and growth rates are estimated on an as-reported basis.
Orthopedic Sales by Segment
1Q22
1Q21
$ Chg
% Chg
Orthobiologics
$26.0
$23.8
$2.2
9.2%
Company Earnings
Amt
% of Sales
Sales
$36.1
Cost of Sales
$12.6
35%
General and Admin
$25.9
71.7%
R & D
$4.9
13.5%
Other
($0.2)
(0.5%)
Net Earnings
($7.1)
(19.7%)
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
Vericel reported 1Q22 orthopedic sales of $26 million, +9.2% vs. 1Q21.
According to the company, MACI vastly outperformed the overall cartilage repair market. Additionally, the Vericel active surgeon population grew in the double digits during the first quarter while March brought the second-highest biopsy volume since launch.
The company...
Vericel reported 1Q22 orthopedic sales of $26 million, +9.2% vs. 1Q21.
According to the company, MACI vastly outperformed the overall cartilage repair market. Additionally, the Vericel active surgeon population grew in the double digits during the first quarter while March brought the second-highest biopsy volume since launch.
The company previously estimated a $10 million backlog coming into 2022 and said the first quarter did little to process it. Still, despite the better than expected start to the year, Vericel opted to maintain its MACI guidance of $132 million to $141 million. That range represents growth been +18% and +26%.
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. Orthopedic sales and growth rates are estimated on an as-reported basis.
Orthopedic Sales by Segment
1Q22
1Q21
$ Chg
% Chg
Orthobiologics
$26.0
$23.8
$2.2
9.2%
Company Earnings
Amt
% of Sales
Sales
$36.1
Cost of Sales
$12.6
35%
General and Admin
$25.9
71.7%
R & D
$4.9
13.5%
Other
($0.2)
(0.5%)
Net Earnings
($7.1)
(19.7%)
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
